The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a [form of liver disease]( ...

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and ...

Novo Nordisk said on Monday that it was launching a new offer for self-paying type 2 diabetes patients in the U.S. to access ...

Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious ...

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

Wegovy becomes the first GLP-1 based therapy authorized for MASH, which affects roughly 5% of U.S. adults, according to the ...

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.